Evidence map›Paper›PMID 36908029›Full record

ArticleJournal of applied toxicology : JAT2023

Whole exome and transcript profiling of liver following aflatoxin B1 exposure in rats.

Julie F Foley, Brian Elgart, Dhiral Phadke, Deepak Mav, Ignacio Tripodi, Nicholas Clausen, Madeleine Weick, Wes Gladwell, Kevin Gerrish, Ruchir Shah and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of applied toxicology : JAT, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Julie F FoleyDivision, National Toxicology Program, NIEHS, Durham, North Carolina, USA.ORCID 0000-0001-9726-2821
Brian ElgartMolecular Genomics Core Laboratory, Signal Transduction Laboratory, Division of Intramural Research, NIEHS, Durham, North Carolina, USA.
Dhiral PhadkeSciome LLC, Durham, North Carolina, USA.
Deepak MavSciome LLC, Durham, North Carolina, USA.
Ignacio TripodiSciome LLC, Durham, North Carolina, USA.
Nicholas ClausenMolecular Genomics Core Laboratory, Signal Transduction Laboratory, Division of Intramural Research, NIEHS, Durham, North Carolina, USA.ORCID 0000-0003-2354-9357
Madeleine WeickMolecular Genomics Core Laboratory, Signal Transduction Laboratory, Division of Intramural Research, NIEHS, Durham, North Carolina, USA.
Wes GladwellMolecular Genomics Core Laboratory, Signal Transduction Laboratory, Division of Intramural Research, NIEHS, Durham, North Carolina, USA.
Kevin GerrishMolecular Genomics Core Laboratory, Signal Transduction Laboratory, Division of Intramural Research, NIEHS, Durham, North Carolina, USA.
Ruchir ShahSciome LLC, Durham, North Carolina, USA.
B Alex MerrickDivision, National Toxicology Program, NIEHS, Durham, North Carolina, USA.
Joint Center for Structural Genomics · USAgBiome (United States) · USNational Humanities Center · US

Funding

Gene Expression and MicroarraysZICES102445 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI GERRISH, KEVIN · 2009 to 2025
$31.6M
ZIA CARCI Carcinogenicity Health Effects innovation Research ProgramZIAES103383 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI PANDIRI, ARUN KUMAR · 2022 to 2025
$13.0M
Intramural NIH HHS ZIA ES103383
6 · The paper itself

Abstract

We recently developed a rat whole exome sequencing (WES) panel and used it to evaluate early somatic mutations in archival liver tissues from F344/N rats exposed to the hepatocarcinogen, Aflatoxin B1 (AFB1), a widely studied, potent mutagen and hepatocarcinogen associated with hepatocellular carcinoma (HCC). Rats were exposed to 1-ppm AFB1 in feed for 14, 90, and 90 days plus a recovery 60-day, non-exposure period (150-day) timepoint. Isolated liver DNA was exome sequenced. We identified 172 sequence variants across all timepoints, of which 101 were non-synonymous variants. Well-annotated genes carried a diverse set of 29 non-synonymous mutations at 14 days, increasing to 39 mutations at 90 days and then decreasing to 33 mutations following the 60-day recovery. Gene Set Enrichment Analysis conducted on previously reported, available RNA expression data of the same exome sequenced archival samples identified altered transcripts in pathways associated with malignant transformation. These included HALLMARK gene sets associated with cell proliferation (MYC Targets Version 1 and Version 2, E2F targets), cell cycle (G2M checkpoint, mitotic spindle), cell death (apoptosis), and DNA damage (DNA repair, UV response Up, Reactive oxygen species) pathways. DriverNet Impact analysis integrated exome-seq and expression data to reveal somatic mutations in Mcm8, Bdp1, and Cct6a that may drive cancer formation. Connectivity with transcript expression changes identified these genes as the top-ranked candidate driver genes associated with hepatocellular transformation. In conclusion, exome sequencing revealed early somatic mutations that may play a role in cancer cell transformation that are translatable to aflatoxin-induced HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAflatoxin B1AnimalsCell Transformation, NeoplasticExomeLiverRatsRats, Inbred F344Aflatoxin B1aflatoxin b1hepatocarcinogenwhole exome sequencing

Identifiers

PMID36908029
PMCPMC13123471
OpenAlexW4324017955

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.